Generic TriCor Availability

TriCor is a brand name of fenofibrate, approved by the FDA in the following formulation(s):

TRICOR (fenofibrate - tablet;oral)

  • Manufacturer: ABBVIE
    Approval date: November 5, 2004
    Strength(s): 48MG [AB], 145MG [RLD] [AB]

Has a generic version of TriCor been approved?

A generic version of TriCor has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to TriCor and have been approved by the FDA:

fenofibrate tablet;oral

  • Manufacturer: LUPIN LTD
    Approval date: December 23, 2011
    Strength(s): 48MG [AB], 145MG [AB]
  • Manufacturer: MYLAN PHARMS INC
    Approval date: December 7, 2012
    Strength(s): 48MG [AB], 145MG [AB]
  • Manufacturer: VALEANT INTL
    Approval date: April 5, 2012
    Strength(s): 48MG [AB], 145MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of TriCor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
    Patent 6,074,670
    Issued: June 13, 2000
    Inventor(s): Stamm; Andre & Seth; Pawan
    Assignee(s): Laboratoires Fournier, S.A.
    The invention provides an immediate-release fenofibrate composition comprising (a) an inert hydrosoluble carrier covered with at least one layer containing fenofibrate in a micronized form having a size less than 20 .mu.m, a hydrophilic polymer and, optionally, a surfactant, the polymer making up at least 20% by weight of (a); and (b) optionally one or several outer phase(s) or layers(s). The invention also provides a method for preparing said composition.
    Patent expiration dates:
    • January 9, 2018
  • Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
    Patent 6,277,405
    Issued: August 21, 2001
    Inventor(s): Stamm; Andre & Seth; Pawan
    Assignee(s): Labaratoires Fournier, S.A.
    The invention provides a micronized fenofibrate composition. The micronized fenofibrate composition has a dissolution of at least 10% in 5 minutes, 20% in 10 minutes, 50% in 20 minutes and 75% in 30 minutes, as measured using the rotating blade method at 75 rpm according to the European Pharmacopoeia, in a dissolution medium constituted by water with 2% by weight polysorbate 80 or with 0.025M sodium lauryl sulfate. The composition can further comprise hydrophilic polymers, surfactants, hydrosoluble carriers, outer phases or layers, or other pharmaceutically acceptable excipients. The immediate-release fenofibrate composition is preferably in the form of a tablet or in the form of granules inside a capsule.
    Patent expiration dates:
    • January 9, 2018
    • January 9, 2018
      ✓ 
      Drug substance
  • Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
    Patent 6,375,986
    Issued: April 23, 2002
    Inventor(s): Niels P.; Ryde & Stephen B.; Ruddy
    Assignee(s): Elan Pharma International Ltd.
    Disclosed are solid dose nanoparticulate compositions comprising a poorly soluble active agent, at least one polymeric surface stabilizer, and dioctyl sodium sulfosuccinate (DOSS). The solid dose compositions exhibit superior redispersibility of the nanoparticulate composition upon administration to a mammal, such as a human or animal. The invention also describes methods of making and using such compositions.
    Patent expiration dates:
    • September 21, 2020
      ✓ 
      Patent use: ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
      ✓ 
      Drug product
  • Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
    Patent 6,589,552
    Issued: July 8, 2003
    Inventor(s): André ; Stamm & Pawan; Seth
    Assignee(s): Laboratoires Fournier, S.A.
    The invention provides fenofibrate compositions comprising granulates. The granulates can comprise micronized fenofibrate, inert hydrosoluble carrier particles, hydrophilic polymers, and, optionally, surfactants.
    Patent expiration dates:
    • January 9, 2018
  • Fenofibrate pharmaceutical composition having high bioavailability
    Patent 6,652,881
    Issued: November 25, 2003
    Inventor(s): André ; Stamm & Pawan; Seth
    Assignee(s): Laboratories Fournier, S.A.
    The invention provides compositions comprising micronized fenofibrate, where the compositions have a dissolution of at least 10% in 5 minutes, 20% in 10 minutes, 50% in 20 minutes and 75% in 30 minutes, as measured using the rotating blade method at 75 rpm according to the European Pharmacopoeia, in a dissolution medium constituted by water with 2% by weight polysorbate 80 or 0.025 M sodium lauryl sulfate.
    Patent expiration dates:
    • January 9, 2018
      ✓ 
      Drug product
    • January 9, 2018
      ✓ 
      Drug substance
  • Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
    Patent 7,037,529
    Issued: May 2, 2006
    Inventor(s): Stamm; André & Seth; Pawan
    Assignee(s): Laboratoires Fournier
    The invention provides an immediate-release fenofibrate composition comprising (a) an inert hydrosoluble carrier covered with at least one layer containing fenofibrate in a micronized form having a size less than 20 μm, a hydrophilic polymer and, optionally, a surfactant, the polymer making up at least 20% by weight of (a); and (b) optionally one or several outer phase(s) or layer(s). The invention also provides a method for preparing said composition.
    Patent expiration dates:
    • January 9, 2018
      ✓ 
      Drug product
  • Fenofibrate pharmaceutical composition having high bioavailabilty
    Patent 7,041,319
    Issued: May 9, 2006
    Inventor(s): Stamm; André & Seth; Pawan
    Assignee(s): Laboratoires Fournier
    The invention provides fenofibrate tablets comprising granulates, wherein the granulates can comprise carrier particles, micronized fenofibrate, and at least one hydrophilic polymer.
    Patent expiration dates:
    • January 9, 2018
      ✓ 
      Drug product
  • Nanoparticulate fibrate formulations
    Patent 7,276,249
    Issued: October 2, 2007
    Inventor(s): Ryde; Tuula & Gustow; Evan E. & Ruddy; Stephen B. & Jain; Rajeev & Patel; Rakesh & Wilkins; Michael John
    Assignee(s): Elan Pharma International, Ltd. Fournier Laboratories Ireland Ltd.
    The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.
    Patent expiration dates:
    • February 21, 2023
      ✓ 
      Drug product
  • Methods of treatment using nanoparticulate fenofibrate compositions
    Patent 7,320,802
    Issued: January 22, 2008
    Inventor(s): Ryde; Tuula & Gustow; Evan E. & Ruddy; Stephen B. & Jain; Rajeev & Patel; Rakesh & Wilkins; Michael John
    Assignee(s): Elan Pharma International, Ltd. Fournier Laboratories Ireland Ltd.
    The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.
    Patent expiration dates:
    • February 21, 2023
      ✓ 
      Patent use: ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Hide
(web4)